ANNOUNCEMENT

MedCity CONVERGE brings together the entire ecosystem to discuss Healthcare Innovation this July.

OrthoCor Medical seeks $1M

February 22, 2010 12:44 pm by | 0 Comments

OrthoCor active-knee-systemST. PAUL, Minnesota — OrthoCor Medical Inc. is seeking to raise $1 million from the sale of equity, warrants or options , according to documents recently filed with the Securities and Exchange Commission.

The company, which raised $1 million from angel investors last year, has so far raised $16,000 from the latest sale, the SEC documents show.

Overall, OrthoCor hopes to raise $3 million to expand its sales and marketing operations. The start-up is close to signing a deal with a Chicago-based wealth management firm for the remaining $2 million, sources say.

In December, OrthoCor, located at the University Enterprise Laboratories incubator in St. Paul, received approval from the Food and Drug Administration for its OrthoCor Active Knee System. The technology employs a brace that delivers electromagnetic energy to soft tissue to reduce post-operative pain and inflammation and minor muscle and joint aches resulting from over-exertion, strains, sprains and arthritis.

CEO John Dinusson, who previously worked at Blumburg Capital, an early stage venture capital firm, and the Initiative Foundation, declined to comment.

Reblog this post [with Zemanta]
Copyright 2013 MedCity News. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

Reserve your seat now for MedCity CONVERGE, to be held July 9-10 in Philadelphia. Discover strategies, solutions and startups in healthcare innovation. Be a part of this gathering where the entire healthcare ecosystem converges.

Know What's Next in Medical Innovation

Get the latest stories, carefully selected by our editorial team, in your inbox each morning.



Thomas Lee

By Thomas Lee

Thomas Lee was the Minnesota Bureau Chief for MedCityNews.
More posts by Author

0 comments

Stay Up To Date

Next Story
UH Case Medical Center spins off Fluence Therapeutics to commercialize photodynamic therapy for psoriasis
Close